Eficacia y tolerabilidad del levetiracetam en pacientes con temblor esencial: datos de un ensayo abierto de 11 semanas de seguimiento

Sanz-Cartagena, P; Fossas, P; Floriach-Robert, M; Serra-Prat, M; Cano, Antonio; Palomeras, E

doi:10.33588/rn.4503.2006227

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A placebo-controlled, double-blind, randomized crossover study [ 105 ], a double-blind placebo-controlled study on the acute effects of levetiracetam [ 106 ], and an open-label study [ 107 ] showed efficacy of levetiracetam in the treatment of ET affecting upper limbs (in the latter, the efficacy was similar to that of primidone and propranolol) [ 107 ]. However, other studies did not show beneficial effects [ 108 - 110 ], and many patients withdrew the treatment because of side effects in one of them [ 109 ]. Three of these studies showed quality rates higher than 50% [ 105 , 106 , 110 ].…”

Section: Other Antiepileptic Drugsmentioning

confidence: 99%

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

Alonso‐Navarro

García‐Martín

Agúndez

et al. 2020

View full text Add to dashboard Cite

Background: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. Methods: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. Results: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. Conclusion: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.